Most Read Articles
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Bedaquiline, delamanid both effective against multidrug-resistant tuberculosis

23 Apr 2020

The new drugs bedaquiline and delamanid appear to be safe and effective in patients with tuberculosis resistant to multiple treatments, according to the results of a study conducted in South Korea.

Researchers looked at 318 patients, among whom 282 (88.7 percent) were treated with the two drugs (bedaquiline, n=107; delamanid, n=108; both concurrently or sequentially, n=67). They evaluated culture conversion rates, interim treatment outcomes at 12 months, and predictors of unfavourable outcomes.

The mean age of the population was 49.3 years, and 197 patients (69.9 percent) were male. Three patients were HIV seropositive, and 151 (53.5 percent) were resistant to quinolone.

The culture conversion rates were 57.4 percent (81/141) at 2 months and 89.4 percent (126/141) at 6 months. The 12-month outcome was favourable in the majority of the population (239/282; 84.8 percent).

Differences in the culture conversion rate or in interim treatment outcomes were not statistically significant according to drug susceptibility test patterns or new drugs used. Further analysis revealed that older age (>60 years) and lower body mass index (<18.5 kg/m2) were significantly associated with unfavourable outcomes at 12 months.

Adverse drug reactions rarely occurred on either bedaquiline or delamanid.

The present data show satisfactory interim treatment results in patients with multidrug-resistant tuberculosis, with no significant differences between the two drugs, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.